Bionomics initiates Phase II clinical trial of anxiety treatment

23-Apr-2015 - Bionomics Limited announced the initiation of a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression. The study will use functional magnetic resonance imaging (fMRI) to assess the effects of BNC210 on brain activity in ...

Bionomics begins Phase 1b study with anxiety drug

02-Feb-2015 - Bionomics Limited has initiated a Phase 1b clinical trial in healthy volunteers of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression.The trial will be conducted by Biotrial International at its facility in Rennes, France and will investigate the ...

Bionomics and Merck enter new research colloboration

25-Jun-2014 - Bionomics Limited announced that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central ...

Bionomics Acquires US-Based Cancer Stem Cell Company Eclipse Therapeutics

Acquisition provides Bionomics with cancer stem cell technology and antibody drug candidates

18-Sep-2012 - Bionomics Limited has acquired San Diego-based private biotechnology company Eclipse Therapeutics Inc in a scrip-based US$10 million deal. With consideration of approximately 23.9 million shares at 41.76 cents per share, Eclipse shareholders, that include NASDAQ-listed Biogen Idec, will own ...

Bionomics launches ovarian cancer trial

24-May-2012 - Bionomics Limited has launched a Phase I/II clinical trial of its vascular disrupting agent BNC105 in women with ovarian cancer. It is anticipated that up to 134 women will be enrolled at 18 sites across Australia, New Zealand and the United States, including sites in Indiana and Wisconsin. The ...

Ironwood Pharmaceuticals and Bionomics announce collaboration research

Companies to Collaborate on Central Nervous System Disorder Opportunity

06-Jan-2012 - Ironwood Pharmaceuticals, Inc. and Bionomics Limited announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics’ investigational anti‐anxiety compound BNC210 and other related compounds. The goal of the ...

Bionomics BNC105 cancer clinical trials reach key milestones

Clinical program to be expanded

04-Aug-2011 - Bionomics Limited provided an update on the status of ongoing clinical trials of BNC105, its proprietary vascular disrupting agent (VDA) for the treatment of solid tumours. The clinical development of BNC105 has undertaken a two-pronged approach involving the use of BNC105 either, in ...

Bionomics anti-axiety drug Phase Ib clinical trials deliver successful results

BNC210 significantly reduced panic symptoms and faster than placebo

31-Mar-2011 - Bionomics Limited has successfully concluded two Phase Ib clinical trials of BNC210 which is being developed as a new generation treatment for anxiety and depression. The two trials of BNC210 were initiated in France in October 2010 following approval by the French Medical Agency AFSSAPS (Agence ...

Benitec’s Hepatitis B RNAi Program with Biomics Biotechnologies Moves to the Next Stage Following Successful Stage 1 Results

23-Feb-2011 - Benitec Limited announced that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus (HBV), conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached agreement ...

European Approval Granted for Two Phase Ib Clinical Trials of Bionomics' BNC210

First trial will evaluate the potential for BNC210 to relieve panic attacks and reduce symptoms of anxiety

06-Oct-2010 - Bionomics Limited announced approval from the French Medical Agency AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante) and the Ethics Committee of the Strasbourg Hospital, CPP (Comité de Protection des Personnes), to perform two advanced Phase I clinical trials with BNC210, ...